supported by the National Natural Science Foundation of China(Nos.22275043,52203184,52293380 and 52293383);Startup Fund of Wenzhou Institute,University of Chinese Academy of Sciences(Nos.WIUCASQD2021022 and WIUCASQD2021019).
Bacterial biofilms present a significant challenge in treating drug-resistant infections,necessitating the development of innovative nanomedicines.In this study,we introduce triclosan-conjugated,lipase-responsive poly...
the National Natural Science Foundation of China(Nos.51973014,52033001 and 21774008);the long-term subsidy mechanism from the Ministry of Finance and the Ministry of Education of PRC for BUCT;the Fundamental Research Funds for the Central Universities of China(Nos.BUCTRC201912,XK1701 and XK18028)。
Nanotheranostics,which combine the therapeutic and diagnostic functions in one integrated system,have received extensive attentions in cancer treatments because they enable non-invasive diagnosis,tumor-targeted drug d...
the National Natural Science Foundation of China(Nos.51922043,52173122 and 31771091);Guangdong Provincial Program(No.2017GC010304);Science and Technology Planning Project of Ganzhou(No.202101074816);Fundamental Research Funds for Central Universities.
The existence of tumor immunosuppressive microenvironment(TIME)is the major determinant for the poor efficacy of current tumor immunotherapy.Tumor-associated macrophages(TAMs)tend to become tumor-promoting M2-like phe...
financial supports from the National Natural Science Foundation of China(Nos.21975169 and 21374066);the Natural Science Foundation of Jiangsu Province(No.BK20171212);Funded by the Priority Academic Program Development(PAPD)of Jiangsu Higher Education Institutions。
In order to overcome the limitation of traditional active nano-therapeutic drugs on tumor targeting efficiency which cannot reach the receptor/target in sufficient amount in the body,in this work,we developed a monocl...